Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase Ib: To estimate the MTD(s) and/or RP2D(s) of oral LGX818 in combination with oral MEK162, and of oral LGX818 in combination with oral MEK162 and oral LEE011 in patients with BRAF V600-dependent advanced solid tumors. Phase II: To assess clinical efficacy of the LGX818 and MEK162 dual combination and LGX818 and MEK162 and LEE011 triple combination.
Critère d'inclusion
- Patients with solid tumors harboring a BRAF V600 mutation